Swedish biotech Anocca secured $46 million in financing to advance the clinical development of VIDAR-1, a first-in-Europe nonviral genome-edited T-cell receptor (TCR) therapy targeting mutant KRAS in pancreatic cancer. The multicenter Phase I trial has commenced patient recruitment across several European hospitals. The funding will support pivotal milestones and pipeline progression, addressing a notoriously hard-to-treat cancer with innovative engineered immune cell therapies designed for precision oncology applications.